Biological and biochemical characterization of a factor produced spontaneously by adherent cells of human immunodeficiency virus-infected patients inhibiting interleukin-2 receptor alpha chain (Tac) expression on normal T cells

Adherent cells from human immunodeficiency virus (HIV)-infected subjects but not from normal blood donors, patients with Gram-positive or -negative bacteremia, active tuberculosis, toxoplasmosis, pulmonary aspergillosis, and cytomegalovirus infection produce spontaneously an activity which inhibits...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical investigation Vol. 87; no. 6; pp. 2048 - 2055
Main Authors Ammar, A, Cibert, C, Bertoli, A M, Tsilivakos, V, Jasmin, C, Georgoulias, V
Format Journal Article
LanguageEnglish
Published Ann Arbor, MI American Society for Clinical Investigation 01.06.1991
Subjects
Online AccessGet full text
ISSN0021-9738
DOI10.1172/JCI115235

Cover

Abstract Adherent cells from human immunodeficiency virus (HIV)-infected subjects but not from normal blood donors, patients with Gram-positive or -negative bacteremia, active tuberculosis, toxoplasmosis, pulmonary aspergillosis, and cytomegalovirus infection produce spontaneously an activity which inhibits alpha chain of interleukin-2 (Tac) expression and interleukin 2 (IL-2) production by normal activated T cells and IL-2 production by these cells. A similar biologic activity was detected in culture supernatants of in vitro HIV-I-infected normal adherent and leukemic U937 cells. Tac-inhibitory activity is not cytotoxic and it could be detected in serum-free conditioned media. Recombinant granulocyte/macrophage colony-stimulating factor and phorbol myristate acetate stimulation of patients' and normal adherent cells did not enhance specifically the production of the Tac inhibitor. Biologically active conditioned media did not contain infectious virus as well as secreted p24, gp120 viral proteins; the biologic activity could not be abolished by anti-p24, anti-gp120, and anti-nef monoclonal antibodies or human purified polyclonal anti-HIV IgG. Gel filtration of conditioned media followed by anion exchange chromatography resulted in a 1,200-fold degree of purification and revealed that the biologically active molecule was cationic. Sodium dodecyl sulfate polyacrylamide gel electrophoresis of this fraction and gel elution of the proteins showed that the biologic activity was associated with a 29-kD protein which was distinct from alpha- or gamma-interferon, tumor necrosis factor-alpha, and prostaglandin E2. The above findings demonstrate the production of inhibitory factor(s) during HIV infection, which might be involved in the pathogenesis of the patients' immune defect.
AbstractList Adherent cells from human immunodeficiency virus (HIV)-infected subjects but not from normal blood donors, patients with Gram-positive or -negative bacteremia, active tuberculosis, toxoplasmosis, pulmonary aspergillosis, and cytomegalovirus infection produce spontaneously an activity which inhibits alpha chain of interleukin-2 (Tac) expression and interleukin 2 (IL-2) production by normal activated T cells and IL-2 production by these cells. A similar biologic activity was detected in culture supernatants of in vitro HIV-I-infected normal adherent and leukemic U937 cells. Tac-inhibitory activity is not cytotoxic and it could be detected in serum-free conditioned media. Recombinant granulocyte/macrophage colony-stimulating factor and phorbol myristate acetate stimulation of patients' and normal adherent cells did not enhance specifically the production of the Tac inhibitor. Biologically active conditioned media did not contain infectious virus as well as secreted p24, gp120 viral proteins; the biologic activity could not be abolished by anti-p24, anti-gp120, and anti-nef monoclonal antibodies or human purified polyclonal anti-HIV IgG. Gel filtration of conditioned media followed by anion exchange chromatography resulted in a 1,200-fold degree of purification and revealed that the biologically active molecule was cationic. Sodium dodecyl sulfate polyacrylamide gel electrophoresis of this fraction and gel elution of the proteins showed that the biologic activity was associated with a 29-kD protein which was distinct from alpha- or gamma-interferon, tumor necrosis factor-alpha, and prostaglandin E2. The above findings demonstrate the production of inhibitory factor(s) during HIV infection, which might be involved in the pathogenesis of the patients' immune defect.
Adherent cells from human immunodeficiency virus (HIV)-infected subjects but not from normal blood donors, patients with Gram-positive or -negative bacteremia, active tuberculosis, toxoplasmosis, pulmonary aspergillosis, and cytomegalovirus infection produce spontaneously an activity which inhibits alpha chain of interleukin-2 (Tac) expression and interleukin 2 (IL-2) production by normal activated T cells and IL-2 production by these cells. The above findings demonstrate the production of inhibitory factor(s) during HIV infection, which might be involved in the pathogenesis of the patients' immune defect.
Adherent cells from human immunodeficiency virus (HIV)-infected subjects but not from normal blood donors, patients with Gram-positive or -negative bacteremia, active tuberculosis, toxoplasmosis, pulmonary aspergillosis, and cytomegalovirus infection produce spontaneously an activity which inhibits alpha chain of interleukin-2 (Tac) expression and interleukin 2 (IL-2) production by normal activated T cells and IL-2 production by these cells. A similar biologic activity was detected in culture supernatants of in vitro HIV-I-infected normal adherent and leukemic U937 cells. Tac-inhibitory activity is not cytotoxic and it could be detected in serum-free conditioned media. Recombinant granulocyte/macrophage colony-stimulating factor and phorbol myristate acetate stimulation of patients' and normal adherent cells did not enhance specifically the production of the Tac inhibitor. Biologically active conditioned media did not contain infectious virus as well as secreted p24, gp120 viral proteins; the biologic activity could not be abolished by anti-p24, anti-gp120, and anti-nef monoclonal antibodies or human purified polyclonal anti-HIV IgG. Gel filtration of conditioned media followed by anion exchange chromatography resulted in a 1,200-fold degree of purification and revealed that the biologically active molecule was cationic. Sodium dodecyl sulfate polyacrylamide gel electrophoresis of this fraction and gel elution of the proteins showed that the biologic activity was associated with a 29-kD protein which was distinct from alpha- or gamma-interferon, tumor necrosis factor-alpha, and prostaglandin E2. The above findings demonstrate the production of inhibitory factor(s) during HIV infection, which might be involved in the pathogenesis of the patients' immune defect.Adherent cells from human immunodeficiency virus (HIV)-infected subjects but not from normal blood donors, patients with Gram-positive or -negative bacteremia, active tuberculosis, toxoplasmosis, pulmonary aspergillosis, and cytomegalovirus infection produce spontaneously an activity which inhibits alpha chain of interleukin-2 (Tac) expression and interleukin 2 (IL-2) production by normal activated T cells and IL-2 production by these cells. A similar biologic activity was detected in culture supernatants of in vitro HIV-I-infected normal adherent and leukemic U937 cells. Tac-inhibitory activity is not cytotoxic and it could be detected in serum-free conditioned media. Recombinant granulocyte/macrophage colony-stimulating factor and phorbol myristate acetate stimulation of patients' and normal adherent cells did not enhance specifically the production of the Tac inhibitor. Biologically active conditioned media did not contain infectious virus as well as secreted p24, gp120 viral proteins; the biologic activity could not be abolished by anti-p24, anti-gp120, and anti-nef monoclonal antibodies or human purified polyclonal anti-HIV IgG. Gel filtration of conditioned media followed by anion exchange chromatography resulted in a 1,200-fold degree of purification and revealed that the biologically active molecule was cationic. Sodium dodecyl sulfate polyacrylamide gel electrophoresis of this fraction and gel elution of the proteins showed that the biologic activity was associated with a 29-kD protein which was distinct from alpha- or gamma-interferon, tumor necrosis factor-alpha, and prostaglandin E2. The above findings demonstrate the production of inhibitory factor(s) during HIV infection, which might be involved in the pathogenesis of the patients' immune defect.
Author Cibert, C
Jasmin, C
Tsilivakos, V
Georgoulias, V
Bertoli, A M
Ammar, A
AuthorAffiliation Unité d'Oncogénèse Appliquée, Institut National de la Santé et de la Recherche Médicale Unité 268, Hôpital Paul Brousse, Villejuif, France
AuthorAffiliation_xml – name: Unité d'Oncogénèse Appliquée, Institut National de la Santé et de la Recherche Médicale Unité 268, Hôpital Paul Brousse, Villejuif, France
Author_xml – sequence: 1
  givenname: A
  surname: Ammar
  fullname: Ammar, A
– sequence: 2
  givenname: C
  surname: Cibert
  fullname: Cibert, C
– sequence: 3
  givenname: A M
  surname: Bertoli
  fullname: Bertoli, A M
– sequence: 4
  givenname: V
  surname: Tsilivakos
  fullname: Tsilivakos, V
– sequence: 5
  givenname: C
  surname: Jasmin
  fullname: Jasmin, C
– sequence: 6
  givenname: V
  surname: Georgoulias
  fullname: Georgoulias, V
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=5413712$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/1904071$$D View this record in MEDLINE/PubMed
BookMark eNqFUstu1DAUzaKotIUFH4DkBUJ0EWo7jpMsWJRRgaJKbIZ15DjXkwuJHeykYvjd_gjOzGh4CImVH_ece86x73lyYp2FJHnG6GvGCn71cXXLWM6z_CQ5o5SztCqy8nFyHsIXSpkQuThNTllFBS3YWfLwFl3vNqhVT5RtSYNOdzDszrpTXukJPP5QEzpLnCGKmHjlPBm9a2cNLQmjs5Oy4ObQb0mzJartwIOdiIa-DwupmwdlCQ7DbF0LBjWC1Vtyj34OKVoDUaQlYxSJtEDQdtjghHYTt1G-h_kr2pQTDxrGRVz1Y6cWf2jJq7XSlwS-jx5C2Lm0xDo_xADrvYUnySOj-gBPD-tF8vndzXr1Ib379P52dX2XasGrKZUyZ7It20azBrThbVMInkFTlWWeFbQCQcuspDIzSmS8KDIuJa-MqUwDtDSQXSRv9n3HuRmg1TGMV309ehyU39ZOYf1nxWJXb9x9zStZSRb5Lw98777NEKZ6wLAk2L9uXdK84oUs_wtkkgpOpYjA5787Olo5fH-svzjUVYg_bryyGsMRlguWFYxH2OUepr0LwYP51YjWy9DVx6GL2Ku_sBqn3fjEyNj_g_ETUW3hnw
CODEN JCINAO
CitedBy_id crossref_primary_10_1016_0925_4439_92_90104_U
crossref_primary_10_1016_S0248_8663_97_84392_5
crossref_primary_10_1111_j_1749_6632_1993_tb35912_x
crossref_primary_10_1007_BF02918280
crossref_primary_10_1046_j_1537_2995_1997_37197176953_x
ContentType Journal Article
Copyright 1992 INIST-CNRS
Copyright_xml – notice: 1992 INIST-CNRS
DBID AAYXX
CITATION
IQODW
CGR
CUY
CVF
ECM
EIF
NPM
7T5
7U9
H94
7X8
5PM
DOI 10.1172/JCI115235
DatabaseName CrossRef
Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Immunology Abstracts
Virology and AIDS Abstracts
AIDS and Cancer Research Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
AIDS and Cancer Research Abstracts
Immunology Abstracts
Virology and AIDS Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
AIDS and Cancer Research Abstracts
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EndPage 2055
ExternalDocumentID PMC296961
1904071
5413712
10_1172_JCI115235
Genre Research Support, Non-U.S. Gov't
Journal Article
GroupedDBID ---
-~X
.55
.GJ
29K
2WC
3O-
53G
5GY
5RE
8F7
AAWTL
AAYXX
ABOCM
ACGFO
ACIHN
ACNCT
ACPRK
ADBBV
AEAQA
AENEX
AFFNX
AHMBA
AI.
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
CITATION
CS3
D-I
DIK
DU5
E3Z
EBS
EJD
EMB
F5P
FRP
GROUPED_DOAJ
GX1
HYE
H~9
IAO
IEA
IHR
INH
IOF
IPO
J5H
KQ8
L7B
M1P
MVM
N4W
OK1
OVT
P2P
P6G
RPM
TEORI
TR2
TVE
VH1
VVN
W2D
WH7
WOQ
WOW
X7M
YOC
ZGI
ZXP
ZY1
.XZ
08G
08P
354
36B
5RS
7RV
7X7
88E
8AO
8FE
8FH
8FI
8FJ
8R4
8R5
AAKAS
ABPMR
ABUWG
ADZCM
AFCHL
AFKRA
ASPBG
AVWKF
AZFZN
BBNVY
BCR
BCU
BEC
BENPR
BHPHI
BKEYQ
BLC
BPHCQ
BVXVI
CCPQU
EBD
EMOBN
EX3
FEDTE
FYUFA
HCIFZ
HMCUK
HVGLF
IHW
IOV
IQODW
ISR
ITC
LK8
M5~
M7P
NAPCQ
OBH
OCB
ODZKP
OFXIZ
OGEVE
OHH
OHT
OVD
OVIDX
PHGZM
PHGZT
PJZUB
PPXIY
PQGLB
PQQKQ
PROAC
PSQYO
Q2X
S0X
SJFOW
SV3
UHU
UKHRP
XSB
YFH
YHG
YKV
~H1
3V.
88A
AAYOK
CGR
CUY
CVF
ECM
EIF
INR
M0L
NPM
PKN
7T5
7U9
H94
7X8
5PM
ID FETCH-LOGICAL-c429t-66516d8dbc1becf2db7423eb98853709e40838063fa43277326629ff9fbe08fe3
ISSN 0021-9738
IngestDate Thu Aug 21 14:02:46 EDT 2025
Thu Sep 04 20:13:49 EDT 2025
Fri Sep 05 09:59:22 EDT 2025
Wed Feb 19 01:12:21 EST 2025
Mon Jul 21 09:12:52 EDT 2025
Tue Jul 01 01:43:32 EDT 2025
Thu Apr 24 23:06:56 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 6
Keywords Infection
Human
Immunopathology
Pathology
Interleukin 2
Viral disease
Exploration
AIDS
Receiver
Molecular biology
Adhesion
Cell
Language English
License CC BY 4.0
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c429t-66516d8dbc1becf2db7423eb98853709e40838063fa43277326629ff9fbe08fe3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
OpenAccessLink http://www.jci.org/articles/view/115235/files/pdf
PMID 1904071
PQID 16042064
PQPubID 23462
PageCount 8
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_296961
proquest_miscellaneous_80592768
proquest_miscellaneous_16042064
pubmed_primary_1904071
pascalfrancis_primary_5413712
crossref_primary_10_1172_JCI115235
crossref_citationtrail_10_1172_JCI115235
ProviderPackageCode CITATION
AAYXX
PublicationCentury 1900
PublicationDate 1991-06-01
PublicationDateYYYYMMDD 1991-06-01
PublicationDate_xml – month: 06
  year: 1991
  text: 1991-06-01
  day: 01
PublicationDecade 1990
PublicationPlace Ann Arbor, MI
PublicationPlace_xml – name: Ann Arbor, MI
– name: United States
PublicationTitle The Journal of clinical investigation
PublicationTitleAlternate J Clin Invest
PublicationYear 1991
Publisher American Society for Clinical Investigation
Publisher_xml – name: American Society for Clinical Investigation
References 6606682 - J Immunol Methods. 1983 Dec 16;65(1-2):55-63
6235286 - J Immunol. 1984 Sep;133(3):1313-7
2967332 - J Immunol. 1988 Jun 15;140(12):4245-52
2417965 - Int J Cancer. 1986 Feb 15;37(2):247-53
6096719 - Nature. 1984 Dec 20-1985 Jan 2;312(5996):763-7
3485456 - Blood. 1986 Apr;67(4):1063-9
7114072 - Am J Med. 1982 Aug;73(2):171-8
2995487 - J Immunol. 1985 Nov;135(5):3151-62
6328662 - Science. 1984 Jul 6;225(4657):66-9
3663934 - Blood. 1987 Nov;70(5):1267-72
6605980 - J Clin Invest. 1983 Dec;72(6):2072-81
6189183 - Science. 1983 May 20;220(4599):868-71
2665081 - Science. 1989 Jul 21;245(4915):305-8
6318629 - Ann Intern Med. 1984 Jan;100(1):92-106
3114567 - Leuk Res. 1987;11(8):753-60
3011909 - J Immunol. 1986 Jul 1;137(1):323-9
2865566 - Lancet. 1985 Nov 16;2(8464):1083-6
3874021 - Clin Exp Immunol. 1985 May;60(2):285-93
2965728 - J Immunol. 1988 Apr 15;140(8):2639-44
3003749 - Proc Natl Acad Sci U S A. 1986 Feb;83(3):772-6
3349526 - Cell. 1988 Apr 8;53(1):45-53
3490518 - J Immunol Methods. 1986 Nov 6;93(2):157-65
6218186 - J Clin Invest. 1983 Feb;71(2):296-300
2422213 - J Clin Invest. 1986 May;77(5):1712-5
958392 - Nature. 1976 Jul 29;262(5567):401-2
2786762 - Cell Immunol. 1989 Jul;121(2):336-48
3013342 - Blood. 1986 Jul;68(1):281-4
5432063 - Nature. 1970 Aug 15;227(5259):680-5
3281762 - Cell Immunol. 1988 Apr 1;112(2):414-24
3037522 - Proc Natl Acad Sci U S A. 1987 Jul;84(13):4601-5
3871770 - J Biol Chem. 1985 Feb 25;260(4):2345-54
239056 - J Immunol. 1975 Jul;115(1):230-3
2523711 - AIDS. 1989 Mar;3(3):125-33
4128882 - Anal Biochem. 1973 Dec;56(2):502-14
6200935 - Science. 1984 May 4;224(4648):497-500
6609030 - Clin Exp Immunol. 1984 Apr;56(1):14-7
2563266 - J Clin Invest. 1989 Feb;83(2):610-5
References_xml – reference: 6189183 - Science. 1983 May 20;220(4599):868-71
– reference: 6605980 - J Clin Invest. 1983 Dec;72(6):2072-81
– reference: 2523711 - AIDS. 1989 Mar;3(3):125-33
– reference: 2422213 - J Clin Invest. 1986 May;77(5):1712-5
– reference: 2563266 - J Clin Invest. 1989 Feb;83(2):610-5
– reference: 3011909 - J Immunol. 1986 Jul 1;137(1):323-9
– reference: 3874021 - Clin Exp Immunol. 1985 May;60(2):285-93
– reference: 5432063 - Nature. 1970 Aug 15;227(5259):680-5
– reference: 2665081 - Science. 1989 Jul 21;245(4915):305-8
– reference: 2995487 - J Immunol. 1985 Nov;135(5):3151-62
– reference: 6235286 - J Immunol. 1984 Sep;133(3):1313-7
– reference: 2417965 - Int J Cancer. 1986 Feb 15;37(2):247-53
– reference: 239056 - J Immunol. 1975 Jul;115(1):230-3
– reference: 3114567 - Leuk Res. 1987;11(8):753-60
– reference: 958392 - Nature. 1976 Jul 29;262(5567):401-2
– reference: 3037522 - Proc Natl Acad Sci U S A. 1987 Jul;84(13):4601-5
– reference: 2967332 - J Immunol. 1988 Jun 15;140(12):4245-52
– reference: 2965728 - J Immunol. 1988 Apr 15;140(8):2639-44
– reference: 3003749 - Proc Natl Acad Sci U S A. 1986 Feb;83(3):772-6
– reference: 6318629 - Ann Intern Med. 1984 Jan;100(1):92-106
– reference: 2786762 - Cell Immunol. 1989 Jul;121(2):336-48
– reference: 7114072 - Am J Med. 1982 Aug;73(2):171-8
– reference: 6606682 - J Immunol Methods. 1983 Dec 16;65(1-2):55-63
– reference: 6200935 - Science. 1984 May 4;224(4648):497-500
– reference: 6328662 - Science. 1984 Jul 6;225(4657):66-9
– reference: 4128882 - Anal Biochem. 1973 Dec;56(2):502-14
– reference: 3349526 - Cell. 1988 Apr 8;53(1):45-53
– reference: 3281762 - Cell Immunol. 1988 Apr 1;112(2):414-24
– reference: 3013342 - Blood. 1986 Jul;68(1):281-4
– reference: 3485456 - Blood. 1986 Apr;67(4):1063-9
– reference: 6096719 - Nature. 1984 Dec 20-1985 Jan 2;312(5996):763-7
– reference: 3490518 - J Immunol Methods. 1986 Nov 6;93(2):157-65
– reference: 3871770 - J Biol Chem. 1985 Feb 25;260(4):2345-54
– reference: 6218186 - J Clin Invest. 1983 Feb;71(2):296-300
– reference: 3663934 - Blood. 1987 Nov;70(5):1267-72
– reference: 6609030 - Clin Exp Immunol. 1984 Apr;56(1):14-7
– reference: 2865566 - Lancet. 1985 Nov 16;2(8464):1083-6
SSID ssj0014454
Score 1.4529059
Snippet Adherent cells from human immunodeficiency virus (HIV)-infected subjects but not from normal blood donors, patients with Gram-positive or -negative bacteremia,...
SourceID pubmedcentral
proquest
pubmed
pascalfrancis
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 2048
SubjectTerms Biological and medical sciences
Cell Adhesion
Dinoprostone - pharmacology
Granulocyte-Macrophage Colony-Stimulating Factor - pharmacology
HIV Infections - physiopathology
Humans
Immunopathology
Interferon Type I - pharmacology
Interferon-gamma - pharmacology
Medical sciences
Molecular Weight
Opportunistic Infections - immunology
Proteins - chemistry
Proteins - pharmacology
Receptors, Interleukin-2 - drug effects
Retroviridae Proteins - pharmacology
Tetradecanoylphorbol Acetate - pharmacology
Tumor Necrosis Factor-alpha - pharmacology
Title Biological and biochemical characterization of a factor produced spontaneously by adherent cells of human immunodeficiency virus-infected patients inhibiting interleukin-2 receptor alpha chain (Tac) expression on normal T cells
URI https://www.ncbi.nlm.nih.gov/pubmed/1904071
https://www.proquest.com/docview/16042064
https://www.proquest.com/docview/80592768
https://pubmed.ncbi.nlm.nih.gov/PMC296961
Volume 87
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1db9MwFLXGkBASQnxNFBhcIR6GpkCSponzWKZN29jGSyr1LYoTW4020mltEdtf5GfwR7jXTpymK-JDaqMqcR0r98S-1z73mLF3uQhyHvC-4wrBnSCPMicLZO4oHmVF2Jderrk5p2fh4Sg4Hg_GGxs_llhLi7n4kN-szSv5H6viObQrZcn-g2VtpXgCf6N98YgWxuNf2dhsJGnz_UVJ21-Z_P_cCjHfWKcwq3fXIVJWsaCFf-LHoncoMfy_uCZPNCsmUus10YS-ZnmYTfxKSiOZFpL0JnSy5rfyajFzDJULK6rlWYncNSlFOTeZMsQWlYvzsnL8XexZ5SXdXGf3UvtKwh1PspxmJuT3mpFb0fJFRZ70xW5imrHsQLepbNqJtomdZasX0hILhl9r_riF6Z4WE-7MDn_CE1OTJD5s54aTWUmLZOfTZrf4ZnKkS-KyyQqeE0dGQKbp8OsRvrzde7tG9fP2sBKRTO3x3hH6z76RV-lKd599SQ9GJydpsj9O7rC7fhQZzsDRZ7ukFQSDWhLctKiWucKqP9qKO87Rg8tshg9QmQ1W1kVAq0TeJc8oecQe1taAocHnY7Yhqyfs3mlN2njKfrYwBYQpLMEUVmEKUwUZGJhCA1PowBTENTQwBY0P-pOGKazCFLowhQam0MIUOjCFBqagYQoaprCDIH0PLUQBPwaikJgmPGOjg_1k79Cp9xZxcvTA5k4YDryw4IXIPezFlF8IoixIEXP0XyM3lgHGJhz9d5UFfTQnRjmhHysVKyFdrmR_i21W00o-Z9B3lVuEnsDIKggyHgrVj1UsY4Hfgkeqx3Yao6Z5LbxP-79cpDoAj_zU2r_H3tqil0ZtZl2h7Q4ybMkBOqSR5_fYmwYpKY4V9BSMhVIvxCEaY5Dfl-AYbflRyHtsyyCrbUbs0txPj4UdyNnrJFPfvVKVEy1X75MAl_fij_d8ye63r_Artjm_Wsht9Pjn4rV-k34BIOEUTA
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Biological+and+biochemical+characterization+of+a+factor+produced+spontaneously+by+adherent+cells+of+human+immunodeficiency+virus-infected+patients+inhibiting+interleukin-2+receptor+alpha+chain+%28Tac%29+expression+on+normal+T+cells&rft.jtitle=The+Journal+of+clinical+investigation&rft.au=Ammar%2C+A&rft.au=Cibert%2C+C&rft.au=Bertoli%2C+A+M&rft.au=Tsilivakos%2C+V&rft.date=1991-06-01&rft.issn=0021-9738&rft.volume=87&rft.issue=6&rft.spage=2048&rft_id=info:doi/10.1172%2FJCI115235&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0021-9738&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0021-9738&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0021-9738&client=summon